Expression of MMP-2, -7, -9, MT1-MMP and TIMP-1 and -2 has no prognostic relevance in patients with advanced epithelial ovarian cancer

JEAN-LUC BRUN¹,³, ANNIE CORTEZ², BÉNÉDICTE LESIEUR¹, SERGE UZAN¹,⁴, ROMAN ROUZIER¹,⁴* and EMILE DARAÏ¹,⁴*

Departments of ¹Gynecology, and ²Pathology, Hôpital Tenon, AP-HP, F-75571 Paris; ³Department of Obstetrics and Gynecology, Hôpital Pellegrin, Université Bordeaux Segalen, F-33076 Bordeaux; ⁴UPMC University Paris 06, UPRES EA 4053, F-75005 Paris, France

Received June 12, 2011; Accepted September 21, 2011

DOI: 10.3892/or.2011.1608

Correspondence to: Dr Jean-Luc Brun, Department of Obstetrics and Gynecology, Hôpital Pellegrin, Place Amélie Raba Léon, F-33076 Bordeaux, France
E-mail: jean-luc.brun@chu-bordeaux.fr

*Shared senior authorship

Key words: matrix metalloproteinase, prognosis, ovarian neoplasms

Abstract. Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) are involved in tumor invasion, but their prognostic significance is still under discussion. We set out to analyze the epithelial and stromal expression of MMP-2, MMP-7, MMP-9, MT1-MMP, TIMP-1 and TIMP-2 in advanced epithelial ovarian cancers and to assess their prognostic value. A tissue microarray of malignant ovarian tumors from 69 patients was constructed. Immunostaining results were scored using the HSCORE and assessed by univariate analysis with Bonferroni correction and classical multidimensional scaling (CMDS). Kaplan-Meier survival curves calculated with regard to patient and tumor characteristics were compared by the log-rank test. Patients treated by primary surgery (n=43) had a higher tumor size and a trend toward higher epithelial MMP and TIMP expression than those treated by interval surgery (n=26). Optimal cytoreduction (residue ≤1 cm) was obtained in 27 and 18 patients, respectively. Clinical and histological characteristics were not different in patients with optimal cytoreduction and those with suboptimal cytoreduction. The expression of epithelial MMP-9 (P=0.002) and TIMP-2 (P=0.026) were higher in the latter group. CMDS failed to demonstrate any influence of MMP and TIMP expression with regard to cytoreduction outcome. MMP and TIMP expression did not influence survival. Their prognostic values were outweighed by histological type, lymph node involvement and cytoreduction. Standard statistical analysis adjusted after Bonferroni correction and CMDS reduced the relevance of MMPs and TIMPs in the prognosis of patients with advanced ovarian cancer.

Introduction

Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) are controllers of extracellular matrix turnover. Both MMP and TIMP expressions are found to be altered in benign and malignant tumors, as well as during invasion and metastasis which require the breakdown and removal of extracellular matrix (1).

The presence of MMPs in ovarian cancer and their contribution to the invasive phenotype of these tumors have been documented in both in vitro and clinical studies. Immunochemistry and Western blot analysis have shown higher activated MMP-2 in epithelial ovarian carcinomas than in benign tumors (2,3). High levels of MMP-9 have been found in human ovarian carcinoma xenografts and overexpression of MMP-7 in ovarian cancer cell lines and cancer surgical specimens (3,4). MT1-MMP has been shown to regulate cell proliferation, cell mobility, invasiveness and differentiation (5). The expression of TIMP-1 was higher in malignant and borderline tumors than in benign tumors and strong TIMP-2 immunostaining has been found in serous ovarian carcinomas (6,7).

About 15 studies have been published on the prognostic value of MMP-2, MMP-7, MMP-9, MT1-MMP, TIMP-1 or TIMP-2 in ovarian cancers, but the results remain controversial. Most of these MMPs and TIMPs have been shown to be overexpressed in tumors, peritoneal implants or metastatic lesions, and associated with poor outcome (2,8-13). On the other hand, a strong MMP-2, MMP-9 or MMP-7 signal in cancer cells has been found to predict better survival (14-16). However, most of the previous studies evaluated MMPs and TIMPs separately in ovarian neoplasms, and little is known of their concomitant expression in epithelial ovarian cancers. We therefore, used a translational approach to analyze the epithelial and stromal expressions of MMP-2, MMP-7, MMP-9, MT1-MMP, TIMP-1 and TIMP-2 in advanced epithelial ovarian cancers and to assess their prognostic value.
Materials and methods

Patients and tumors. Ovarian tissue samples were obtained from all the patients who underwent surgery consecutively for FIGO stage III and IV epithelial ovarian cancer in the Gynecology Department of Tenon Hospital, Paris, from 2001 to 2006.

All the tumors were reviewed to confirm histological diagnosis. Histological typing followed the FIGO recommendations (17). Epidemiological characteristics, recurrence and survival were recorded for all patients. The study was approved by the Ethics Committee of the College National des Gynécologues et Obstétriciens Français.

Tissue microarray (TMA) and immunohistochemistry. Formalin-fixed, paraffin-embedded tumor samples were used to construct a TMA, as previously described (18). Briefly, after selection of a representative tumor region from each tumor block, tissue cylinders were punched with the use of a custom-made precision instrument (Beecher Instruments, Silver Spring, MD) and transferred to a 25 x 35 mm paraffin block under microscopic control. TMA blocks were cut into 4 µm sections and transferred to glass slides (19). Separate sections from the TMA blocks were used for immunohistochemical analysis, using the Ventana Nexes automated immunohistochemistry system (Ventana Medical Systems, Tucson, AZ).

Purified mouse monoclonal or rabbit polyclonal antibodies against human MMP-2,-7,-9, MT1-MMP, TIMP-1, and -2 were used as primary antibodies at various concentrations: MMP-2 (mouse; clone 42-5D11; Calbiochem, San Diego, CA; 5 µg/ml), MMP-7 (mouse; clone ID2; Lab Vision Corp., Fremont, CA; 1.3 µg/ml), MMP-9 (mouse; clone 56-2A4; Calbiochem; 20 µg/ml), MT1-MMP (rabbit; Lab Vision Corp.; 8 µg/ml), TIMP-1 (mouse; clone 102D1; Lab Vision Corp.; 8 µg/ml), and TIMP-2 (mouse; clone 3A4; Lab Vision Corp.; 4 µg/ml).

Prior to the primary antibody staining an antigen retrieval step was used combined with a high temperature antigen-unmasking technique (Dako Target Retrieval Solution, Glostrup, Denmark; 100°C; 30 min). For MMP-7, antigen unmasking was achieved with proteinase K, 4 min. The automated procedure is based on an indirect biotin-avidin system with a universal biotinylated immunoglobulin as secondary antibody, diaminobenzidine as substrate, and hematoxylin as counterstain. Except for MT1-MMP, a Ventana amplification kit was used in addition to the automated procedure (Ventana Medical Systems).

Positive controls for MMP-2, MMP-7, MMP-9, MT1-MMP, TIMP-1 and TIMP-2 were sections of endometrial cancers which had been strongly stained in a previous study (20). For negative control, the primary antibody was replaced by an irrelevant non-immune mouse antibody of the same immunoglobulin G subtype.

Semiquantitative analysis. The TMA was analyzed by light microscopy by use of a x10 objective. Immunostaining results were scored by JLB and AC independently, using the HSCORE (21). The HSCORE was produced by multiplying the percentage of stained tumor cells (0-100%) with the intensity score. The intensity of staining was scored on a 4-point scale: 0, no staining; 1, weak; 2, moderate; 3, intense. Thus, each score ranged 0-300. For each tumor specimen, the HSCORE of a given MMP or TIMP was assessed in epithelial and stromal cells. Discordance between the two examiners never exceeded 5%.

Statistical analysis. Continuous variables were compared with Student's t-test and categorical variables were compared with the χ² test or Fisher's exact test, as appropriate. P-values <0.05 were considered statistically significant. Because of multiple comparisons in MMP and TIMP expressions, Bonferroni correction was used to determine the significance levels of two-tailed P-values (22). This was achieved by dividing the common P-value border 0.05 by the number of comparisons.

Unsupervised analysis was performed to organize the results of TMA immunostaining into meaningful structures. Classical Multidimensional Scaling (CMDS), also known as Principal Component Analysis, is a transformation procedure used to reduce multidimensional data sets to lower dimensions for analysis. This procedure provides information about the spatial ‘proximity’ (similarity) or ‘distance’ (difference) in a multidimensional space where each dimension is one marker of the panel. Results of CMDS can be plotted into the most informative two-dimensional construction in which one point represents one tumor.

The performance of each MMP was quantified with respect to discrimination. Discrimination (i.e., whether the relative ranking of individual predictions is in the correct order) was quantified with the concordance index (C index) and its 95% confidence interval, which is similar to the area under the receiver operating characteristic curve (AUROC) but appropriate for censored data. The C index is the probability that given two randomly selected patients, the patient with the worse score will actually have a worse outcome. It ranges from 0 to 1, with 1 indicating perfect concordance, 0.5 indicating no better concordance than chance, and 0 indicating perfect discordance. The optimal threshold for each MMP was determined using the function ‘optimal.thresholds’ (PresenceAbsence) of the R package.

Survival curves were constructed according to Kaplan-Meier method. Survival was defined from primary surgery or the beginning of neoadjuvant chemotherapy to date of death and evaluated in 2007. Kaplan-Meier survival curves were calculated using univariate analysis and compared by the log-rank test. Statistical significance was set at P<0.05.

All analyses were performed using the R package (http://lib.stat.cmu.edu/R/CRAN/).

Results

Patients and tumors. Out of the 69 patients included, 43 (62%) underwent primary surgery and the remaining 26 (38%) were treated by neoadjuvant chemotherapy followed by interval surgery. Clinical and biological characteristics were not significantly different between the groups: median age 64 years (range 26–84) and 62 years (range 21-76) respectively; FIGO stages III in 41/43 patients (95%) and 22/26 patients (85%), respectively; peritoneal carcinomatosis in 35/43 patients (81%) and 18/26 patients (69%), respectively; median CA125 plas-
matic level 395 U/ml (range 43-8845) and 988 U/ml (range 34-31210), respectively.

Epithelial and stromal expressions of MMPs and TIMPs were determined in 92% (range, 89-94) and 98% (range, 97-99) of tissue samples. Immunostaining data for all markers were available in 58 of the 69 patients (84%). The mean (SD) epithelial HSCORE values of MMPs and TIMPs were as follows: MMP-2, 96 (47); MMP-7, 66 (59); MMP-9, 133 (47); MT1-MMP, 120 (67); TIMP-1, 84 (44); TIMP-2, 151 (46). The mean (SD) stromal HSCORE values of MMPs and TIMPs were as follows: MMP-2, 31 (40); MMP-7, 11 (19); MMP-9, 25 (19); MT1-MMP, 11 (12); TIMP-1, 6 (8); TIMP-2, 31 (23). Representative cases of haematoxylin-eosin stained sections, MMP-9 expression and TIMP-2 expression in two specimens are shown in Fig. 1.

The histological and immunohistological characteristics of the tumors according to primary or interval surgery are shown in Table I. No histological difference was observed between the groups except for tumor size which was significantly reduced after neoadjuvant chemotherapy. Immunohistochemistry showed epithelial expressions of MMPs and TIMPs to be higher in tumors from patients treated by primary surgery than those undergoing interval surgery. P-values <0.05 were obtained for epithelial MT1-MMP and TIMP-2. However, none of these differences remained significant after Bonferroni correction.

Cytoreductive surgery. Cytoreductive surgery was considered optimal (residual tumor ≤1 cm) in 27/43 patients (63%) treated by primary surgery and in 18/26 patients (69%) treated by interval surgery. Clinical and biological characteristics (age, FIGO stage, CA125 plasmatic level) were not significantly different in patients with optimal cytoreduction and in patients with suboptimal cytoreduction. However, peritoneal carcinomatosis was present in 30/45 patients (66%) with optimal cytoreduction and in 22/24 patients (96%) with suboptimal cytoreduction (P=0.007).

The histological and immunohistological characteristics of the tumors according to optimal or suboptimal cytoreduc-
tion are shown in Table II. There was no significant histological difference between the groups. Lymphovascular space involvement tended to be more present in tumors from patients with suboptimal cytoreduction. Immunohistochemistry showed that expressions of epithelial MMP-9 and TIMP-2 were higher in patients with suboptimal cytoreduction than in patients with optimal cytoreduction (P<0.05). However, only the difference in epithelial MMP-9 was considered significant after Bonferroni correction. The epithelial and stromal levels of the other MMPs and TIMPs were not different in tumors from patients with optimal or suboptimal cytoreduction.

In patients treated by primary surgery, the expression of epithelial MMP-9 was higher in patients with suboptimal cytoreduction: mean (SD) HSCORE values 160 (45) and 127 (41), respectively, P=0.019. In patients treated by interval surgery, the

| Tumor characteristics | Primary surgery (n=43) (%) | Interval surgery (n=26) (%) | P-valuea |
|-----------------------|---------------------------|---------------------------|----------|
| Tumor size (mm)       | 96 (47)                   | 69 (53)                   | 0.042    |
| Histology             |                           |                           |          |
| Serous (n=40)         | 24 (56)                   | 16 (61)                   | 0.236    |
| Mucinous (n=2)        | 1 (2)                     | 1 (4)                     |          |
| Endometrioid (n=15)   | 9 (21)                    | 6 (23)                    |          |
| Clear cells (n=7)     | 7 (16)                    | 0                         |          |
| Other (n=5)           | 2 (5)                     | 3 (12)                    |          |
| Grade                 |                           |                           | 0.867    |
| Well differentiated (n=7) | 5 (12)                  | 2 (8)                     |          |
| Moderately differentiated (n=32) | 19 (44)            | 13 (50)                   |          |
| Poorly differentiated (n=26) | 17 (39)               | 9 (34)                    |          |
| Not determined (n=4)  | 2 (5)                     | 2 (8)                     |          |
| Lymphovascular space involvement |                   |                           | 0.320    |
| No (n=46)             | 26 (61)                   | 20 (77)                   |          |
| Yes (n=22)            | 16 (37)                   | 6 (23)                    |          |
| Not determined (n=1)  | 1 (2)                     | 0                         |          |
| Lymph node involvement when sampled |                       |                           | 0.405    |
| Not involved, N- (n=15) | 8 (33)                   | 7 (47)                    |          |
| Involved, N+ (n=24)   | 16 (66)                   | 8 (53)                    |          |
| MMP-2                 |                           |                           | 0.689    |
| Epithelial            | 98 (43)                   | 93 (54)                   |          |
| Stromal               | 25 (37)                   | 41 (43)                   |          |
| MMP-7                 |                           |                           | 0.192    |
| Epithelial            | 73 (66)                   | 54 (43)                   |          |
| Stromal               | 9 (16)                    | 15 (23)                   |          |
| MMP-9                 |                           |                           | 0.125    |
| Epithelial            | 139 (45)                  | 121 (48)                  |          |
| Stromal               | 25 (21)                   | 25 (17)                   |          |
| MT1-MMP               |                           |                           | 0.049    |
| Epithelial            | 132 (72)                  | 97 (49)                   |          |
| Stromal               | 12 (15)                   | 8 (7)                     |          |
| TIMP-1                |                           |                           | 0.804    |
| Epithelial            | 85 (46)                   | 82 (42)                   |          |
| Stromal               | 6 (8)                     | 7 (8)                     |          |
| TIMP-2                |                           |                           | 0.041    |
| Epithelial            | 159 (44)                  | 135 (47)                  |          |
| Stromal               | 31 (26)                   | 31 (17)                   |          |

Quantitative values are reported by using mean (SD). P-value <0.05 was considered as significant for histological data. P-value <0.004 was considered as significant for immunohistological data after Bonferroni correction. Bold text, statistically significant.
epithelial and stromal levels of MMPs and TIMPs were not different in tumors from patients with optimal or suboptimal cytoreduction.

CMDS showed that the tumors distributed homogeneously, independently from the surgical outcome (Fig. 2) indicating that the outcome of cytoreductive surgery was poorly influenced by MMP and TIMP profile of the tumors.

**Survival.** Survival was assessed according to clinical, histological and immunohistological data. The median follow-up was 24 months (range 7-78). As expected, the 2-year survival probability differed significantly according to surgical outcome: 86% in patients with optimal cytoreduction and 63% in patients with suboptimal cytoreduction (Table III). Survival was also negatively influenced by tumors with clear cell/other...
histological types or with lymph node involvement. However, lymphovascular space involvement did not influence survival. The performance of MMPs and TIMPs for survival quantified with the C index was poor. The AUROC values ranged from 0.48 to 0.65 (Table IV). P-values <0.05 were obtained for epithelial MT1-MMP and TIMP-2. However, none of these differences remained significant after Bonferroni correction. Survival was negatively influenced by positive expressions of epithelial TIMP-2 and stromal TIMP-1. Again, none of these differences remained significant after Bonferroni correction.

**Discussion**

This study confirms the relevance of MMPs and TIMPs as markers of tumor proliferation and invasiveness as their epithelial expressions were relatively high in advanced ovarian cancers. However, we failed to demonstrate that they were of any prognostic value as the distribution of the tumors was scattered in the CMDS model and not influenced by the quality of cytoreduction. In addition, MMP and TIMP expressions were found not to influence survival.

In the present study, MMP and TIMP expressions were higher in the epithelium than in the stroma of ovarian cancers with mean HSCORE values ranging from 66-151 and 6-31, respectively. It has already been demonstrated that high levels of epithelial MMPs and TIMPs are not actually specific for malignant tumors. For example, MMP-2 signal was shown to be present in 76% of malignant tumors and 54% of benign tumors on immunohistochemical analysis (2). Another study found MMP-2 to be more frequently expressed in benign tumors with morphological altered lesions than in established carcinomas (23). Similar MMP-7 profiles have been observed in mucinous tumors whatever their benign, borderline or malignant nature (24). MT1-MMP mRNA was shown to be strongly expressed both in borderline and malignant tumors (25). High TIMP-2 expressions have been found in malignant tumors compared to borderline and benign ovarian tumors while various expressions were observed for TIMP-1 in the same figure (26,27). MMP-9 is probably the least controversial. Stronger epithelial MMP-9 expressions have been reported in malignant tumors than in benign or borderline tumors (28,29).

These discrepancies between studies can be partly explained by different methods of analysis and detection and also because the MMP and TIMP values were evaluated separately rather than by a translational approach. In a previous study using the same scoring system, we found alterations in all MMP and TIMP expressions in malignant serous tumors compared to benign and borderline tumors in univariate analysis (18). By cluster analysis, only MT1-MMP, MMP-7 and MMP-9 could distinguish malignant serous tumors from borderline and benign ovarian tumors. By CMDS analysis, the tumors were distributed first according to the mucinous or serous histological type, then according to the benign, borderline or malignant nature of the tumor. The influence of histological type has also been underlined in a study showing high level expressions of MMP-2 and MT1-MMP in ovarian clear cell carcinoma relative to other histotypes (30).

---

Table III. Patient and tumor characteristics and survival outcome.

| Characteristics                  | Disease-free survival (%) | P-valuea |
|----------------------------------|---------------------------|----------|
| Histology                        |                           |          |
| Serous (n=41)                    | 80                        |          |
| Mucinous (n=2)                   | NA                        |          |
| Endometrioid (n=15)              | 87                        |          |
| Clear cells (n=7)                | 67                        |          |
| Other (n=3)                      | 33                        |          |
| Grade                            |                           |          |
| Well differentiated (n=7)         | 100                       | 0.874    |
| Moderately differentiated (n=32) | 75                        |          |
| Poorly differentiated (n=29)      | 73                        |          |
| Lymphovascular space involvement|                           | 0.963    |
| No (n=76)                        | 78                        |          |
| Yes (n=22)                       | 74                        |          |
| Lymph node                       |                           |          |
| Not involved, N- (n=15)          | 100                       | <0.001   |
| Involved, N+ (n=24)              | 81                        |          |
| Not sampled, Nx (n=30)           | 61                        |          |
| FIGO stage                       |                           | 0.492    |
| III (n=63)                       | 76                        |          |
| IV (n=6)                         | 83                        |          |
| Cytoreduction                    |                           |          |
| Optimal (n=45)                   | 86                        | 0.002    |
| Suboptimal (n=24)                | 63                        |          |

aP-value <0.05 was considered as significant for clinical and histological data. Bold text, statistically significant.
In the present study, tumors from patients with optimal cytoreduction demonstrated low epithelial MMP-9 expression by univariate analysis. The other expressions were not discriminative. In addition, CMDS failed to demonstrate any influence of MMPs and TIMPs on the quality of cytoreduction.

The prognostic impact of MMP-9 has been underlined in two studies assessing the latent and the active forms of gelatinases by zymography. In one study, it was found that only MMP-9, but not MMP-2, had an impact on recurrence (31). Activities of proMMP-9 (the latent form of MMP-9) and active MMP-9 in the tumor were higher in patients with recurrence. However, no values were available on the quality of cytoreduction in this study. In the other study, only proMMP-9 had an impact on prognosis (32). ProMMP-9 was associated with short survival only in the subgroup of patients with optimal cytoreduction, while for patients with residual disease proMMP-9 did not predict survival. Therefore, proMMP-9 is of strong prognostic power in patients with no postoperative residual disease.

By immunohistochemistry, epithelial MMP-9 has been associated with no or ≤2 cm residual disease only if there is a strong signal in a high proportion of cancer cells (16). In addition, low stromal MMP-9 expression was significantly related to tumors with no residual disease. These results contrast with ours and the literature. However, we demonstrate in the present study that MMP-9 loses its prognostic impact in terms of cytoreduction once a translation approach is adopted.

Table IV. MMP and TIMP expressions in tumors and survival outcome.

| Characteristics | AUC     | P-value | Negative expression | Positive expression | P-value log-rank |
|-----------------|---------|---------|---------------------|---------------------|------------------|
| MMP-2           |         |         |                     |                     |                  |
| Epithelial      | 0.51    | 0.351   | 53.8                | 57.8                | 0.331            |
| Stromal         | 0.57    | 0.072   | 54.4                | 54.8                | 0.472            |
| MMP-7           |         |         |                     |                     |                  |
| Epithelial      | 0.51    | 0.473   | 54.8                | 46.2                | 0.864            |
| Stromal         | 0.48    | 0.590   | 52.5                | 58.3                | 0.988            |
| MMP-9           |         |         |                     |                     |                  |
| Epithelial      | 0.51    | 0.394   | 53.7                | 54.9                | 0.902            |
| Stromal         | 0.56    | 0.077   | 58.6                | 51.4                | 0.302            |
| MT1-MMP         |         |         |                     |                     |                  |
| Epithelial      | 0.65    | 0.007   | 56.2                | 48                  | 0.371            |
| Stromal         | 0.51    | 0.390   | 52.0                | 56.1                | 0.402            |
| TIMP-1          |         |         |                     |                     |                  |
| Epithelial      | 0.51    | 0.491   | 51.0                | 74                  | 0.093            |
| Stromal         | 0.57    | 0.078   | 58.1                | 40.2                | 0.016            |
| TIMP-2          |         |         |                     |                     |                  |
| Epithelial      | 0.61    | 0.023   | 72.2                | 47.9                | 0.050            |
| Stromal         | 0.57    | 0.077   | 54.4                | 59.0                | 0.456            |

Discrimination of the performance of each MMPs and TIMPs for survival was quantified with the concordance index (C index), which is similar to the area under the receiver operating characteristic curve (AUROC). Different values of the AUROC are close to 0.5, indicating no better concordance than chance. Negative expression was defined by a value under the optimal threshold. Positive expression was defined by a value over the optimal threshold. P-value <0.004 was considered as significant for immunohistological data after Bonferroni correction. No difference in 2-year disease-free survival was observed for MMP and TIMP expressions after Bonferroni correction.
while tumor type, grade and stage did not. In another study assessing MMP-2, MMP-9 and MT1-MMP in 77 patients with ovarian cancer, strong epithelial MT1-MMP and stromal MMP-9 and FIGO stage were independently associated with shorter survival (33). On the other hand, as in our study, clinical (FIGO stage, residual disease) and histological (grade) characteristics were found to be independent prognostic factors and outweighed MMP-9 epithelial and stromal expressions which influenced clinical outcome in univariate analysis (16).

Discrepancies may be explained by the absence of a given threshold for each MMP evaluated by immunohistochemistry as this differs from study to study (16,33). We used the concordance index to evaluate the discrimination of quantitative values of MMPs and TIMPs for survival. With this approach, the alternatives are compared directly, without having to set a possibly arbitrary threshold. In addition, none of the studies mentioned above referred to the Bonferroni correction of P-values in case of multiple tests. Thus, the significance of certain MMPs or TIMPs could be overestimated.

Technically, immunohistochemistry procedures require multiple steps which may cause concern. In a recent study, the HSCORE technique was used to assess the prognostic significance of six biomarkers including gelatinases in a TMA of 185 specimens (34). Unfortunately, MMP-2 and MMP-9 staining was observed at very low levels in serous and endometrioid carcinomas; thus, gelatinase expressions failed to demonstrate any influence in contrast to the other biomarkers studied. In our center, numerous tests were run before finding the best method for antigen unmasking, to select the concentration of primary antibody staining, and to test the advantage of using the Ventana amplification kit.

To conclude, standard statistical analysis adjusted after Bonferroni correction as well as classical multidimensional scaling failed to demonstrate any influence of MMPs and TIMPs in the prognosis of ovarian tumors. Despite the lack of standardized methods for MMP and TIMP detection and the underuse of translational approach in the literature, the impact of MMPs and TIMPs on prognosis is probably less important than previously thought. Further studies must address these concerns as considerable hopes are pinned on the success of targeted therapy in patients with advanced ovarian cancer.

Acknowledgements

The authors thank Anita Rodenas for advice in setting up tissue microarray and for technical assistance in testing MMP antibodies for immunohistochemistry, and Felicity Neilson for reviewing this manuscript.

References

1. Schröper A, Kammerer U, Kapp M, Dietl J, Feix S and Anacker J: Expression pattern of matrix metalloproteinases in human gynecological cancer cell lines. BMC Cancer 13: 553, 2013.

2. Wu X, Li H, Kang L, Wang W and Shan B: Activated matrix metalloproteinase-2: a potential marker of prognosis for epithelial ovarian cancer. Gynecol Oncol 84: 126-134, 2002.

3. Planagumà J, Liljestrom M, Alameda F, et al: Matrix metalloproteinase-2 and matrix metalloproteinase-9 codoctrate with transcription factors RUNX1/AML1 and ETV5/ERM at the invasive front of endometrial and ovarian carcinoma. Hum Pathol 42: 57-67, 2011.

4. Wang FQ, So J, Reierstad S and Fishman DA: Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of proteoglycanase. Int J Cancer 114: 19-31, 2005.

5. Moss NM, Barbolina MV, Liu Y, Sun L, Munshi HG and Stack MS: Ovarian cancer cell detachment and multicellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: a potential role in I.p. metastatic dissemination. Cancer Res 69: 7121-7129, 2009.

6. Huang LW, Garrett AP, Bell DA, Welch WR, Berkowitz RS and Mok SC: Differential expression of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 protein and mRNA in epithelial ovarian tumors. Gynecol Oncol 77: 369-376, 2000.

7. Kim TJ, Rho SB, Choi YL, et al: High expression of tissue inhibitor of metalloproteinase-2 in serous ovarian carcinoma and the role of this expression in ovarian tumorigenesis. Hum Pathol 37: 906-913, 2006.

8. Davidson B, Goldberg I, Gotlieb WH, et al: High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma. Clin Exp Metastasis 17: 799-809, 1999.

9. Davidson B, Reich R, Berner A, et al: Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels. Eur J Cancer 37: 2040-2049, 2001.

10. Davidson B, Goldberg I, Gotlieb WH, Kopolovic J, Ben-Baruch G, Nesland JM and Reich R: The prognostic value of metalloproteinases and angionic factors in ovarian carcinoma. Mol Cell Endocrinol 187: 39-45, 2002.

11. Kamat AA, Fletcher M, Gruman LM, et al: The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res 12: 1707-1714, 2006.

12. Péringy M, Bairati I, Harvey I, et al: Role of immunohistochemical overexpression of matrix metalloproteinases MMP-2 and MMP-11 in the prognosis of death by ovarian cancer. Am J Clin Pathol 129: 226-231, 2008.

13. Raulava M, Puistolu A and Turpeenniem M-Huonen T: Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor. Gynecol Oncol 99: 656-663, 2005.

14. Sillanpää SM, Anttila MA, Voutilainen KA, et al: Prognostic significance of matrix metalloproteinase-7 in epithelial ovarian cancer and its relation to β-catenin. Int J Cancer 119: 1792-1799, 2006.

15. Sillanpää S, Anttila M, Suhonen K, et al: Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase-2 in epithelial ovarian cancer. Tumour Biol 28: 280-289, 2007.

16. Sillanpää S, Anttila M, Voutilainen K, et al: Prognostic significance of matrix metalloproteinase-9 (MMP-9) in epithelial ovarian cancer. Gynecol Oncol 104: 296-303, 2007.

17. Benedet JL, Bender H, Jones III H, Nagan HYS and Pecorelli S: FIGO staging classification and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynecol Obstet 70: 209-262, 2000.

18. Brun JL, Cortez A, Combro F, Uzan S, Rouzier R and Darai E: Serous and mucinous ovarian tumors express different profiles of MMP-2, -7, -9, MT1-MMP, and TIMP-1 and -2. Int J Oncol 33: 1239-1246, 2008.

19. Skacel M, Skilton B, Pettay JD and Tubbs RR: Tissue microarrays: a powerful tool for high-throughput analysis of clinical specimen: a review of the method with validation data. Appl Immunohistochem Mol Morphol 10: 1-6, 2002.

20. Graesslin O, Cortez A, Fauret R, Lorenzato M, Birembaut P and Darai E: Metalloproteinase-2, -7 and -9 and tissue inhibitor of metalloproteinase-1 and -2 expressions in normal, hyperplastic and neoplastic endometrium; a clinical-pathological correlation study. Ann Oncol 17: 637-645, 2006.

21. Budwig-Novotny DA, Mccarty KS, Cox EB, et al: Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res 46: 5419-5425, 1986.

22. Blanch MD and Altman DG: Multiple significance tests: the Bonferroni method. BMJ 310: 170, 1995.

23. Cai KQ, Yang WL, Capo-Chichi CD, et al: Prominent expression of metalloproteinases in early stages of ovarian tumorigenesis. Mol Carcinogen 46: 130-143, 2007.

24. Yamasan K, Tanimoto H, Sakata K, et al: Induction of matrix metalloprotease-7 is common in mucinous ovarian tumors including early stage disease. Med Oncol 17: 52-58, 2000.
25. Afzal S, Lalani EN, Poulson R, et al: MT1-MMP and MMP-2 mRNA expression in human ovarian tumors: possible implications for the role of desmoplastic fibroblasts. Hum Pathol 29: 155-165, 1998.

26. Sakata K, Shigemasa K, Nagai N and Ohama K: Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Int J Oncol 17: 673-681, 2000.

27. Määttä M, Santala M, Soini Y, Talvensaari-Mattila A and Turpeenniemi-Hujanen T: Matrix metalloproteinases 2 and 9 and their tissue inhibitors in low malignant potential ovarian tumors. Tumor Biol 25: 188-192, 2004.

28. Behrens P, Rothe M, Florin A, Wellman A and Wernert N: Invasive properties of serous human epithelial ovarian tumors are related to Ets-1, MMP-1 and MMP-9 expression. Int J Mol Med 8: 149-154, 2001.

29. Ozalp S, Tanir HM, Yalcin OT, Kabukcuoglu S, Oner U and Uray M: Prognostic value of matrix metalloproteinase-9 (gelatinase B) expression in epithelial ovarian tumors. Eur J Gynaecol Oncol 24: 417-420, 2003.

30. Adley BP, Gleason KJ, Yang XJ and Stack MS: Expression of membrane type 1 matrix metalloproteinase (MMP-14) in epithelial ovarian cancer; high level expression in clear cell carcinoma. Gynecol Oncol 112: 319-324, 2009.

31. Demeter A, Sziller I, Capo Z, et al: Molecular prognostic markers in recurrent and in non-recurrent epithelial ovarian cancer. Anticancer Res 25: 2885-2889, 2005.

32. Lengyel E, Schmalfeldt B, Konik E, et al: Expression of latent matrix metalloproteinase 9 (MMP-9) predicts survival in advanced ovarian cancer. Gynecol Oncol 82: 291-298, 2001.

33. Lin YG, Han LY, Kumat AA, et al: EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer 109: 332-334, 2007.

34. Lin CK, Chao TK, Yu CP, Yu MH and Jin JS: The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters. APMIS 117: 162-175, 2009.